Rallybio (FRA:33M0) Marketable Securities: €5.50 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:33M0 Rallybio Corp FRA:33M0
18 GF Score
Price €13.90
! 5 Warning Signs
View Full Analysis

What is Rallybio Marketable Securities?

Rallybio FRA:33M0 -1.42% 18 Marketable Securities is €5.50 Mil as of Mar. 2026. GuruFocus rates FRA:33M0 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Rallybio's Marketable Securities for the quarter that ended in Mar. 2026 was €5.50 Mil.

Rallybio's annual Marketable Securities declined from Dec. 2023 (€85.44 Mil) to Dec. 2024 (€51.61 Mil) and declined from Dec. 2024 (€51.61 Mil) to Dec. 2025 (€23.36 Mil).

Rallybio  (FRA:33M0) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Rallybio Marketable Securities Related Terms

Rallybio Marketable Securities Historical Data

* Premium members only.

The historical data trend for Rallybio's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rallybio Marketable Securities Chart

Rallybio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 112.04 85.44 51.61 23.36

Rallybio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.72 36.30 27.20 23.36 5.50
FRA:33M0
18GF Score
Rallybio Corp FRA:33M0
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rallybio Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €5.50 Mil mean?
Rallybio (FRA:33M0) has a Marketable Securities of €5.50 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Rallybio and its competitors.
Is Rallybio's Marketable Securities too high?
Rallybio's current Marketable Securities is €5.50 Mil. Overall, Rallybio has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rallybio's Marketable Securities compare to VRCA and HRTX?
Rallybio's Marketable Securities of €5.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Rallybio and its competitors. Rallybio's current Marketable Securities is €5.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rallybio stock overvalued right now?
Rallybio (FRA:33M0) has a current Marketable Securities of €5.50 Mil. The current Marketable Securities is €5.50 Mil. Rallybio's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Rallybio (FRA:33M0), the current Marketable Securities is €5.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rallybio Business Description

Other Exchanges RLYB:USA
Address 234 Church Street, Suite 1020, New Haven, CT, USA, 06510
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
18GF Score

Get the complete analysis for FRA:33M0

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.90
Price